drugset / Trial / NCT00631475
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2008-04
- Primary completion
- 2010-04
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | 62.5 mg | Oral |
| Subject | Bosentan | Other / unclassified | 125 mg | Oral |